Biomarker driven immune therapy for colorectal cancer.
We have demonstrated that histone deacetylase inhibitors (HDACi) can reinstate immune reactivity in colorectal cancer cells by upregulation of elements of the machinery of immune presentation, including MHC class1. We went on to show that the combination of an HDACi with an immune checkpoint inhibitor delivered synergistic anticancer effects in a syngeneic colorectal cancer (CRC) mouse model. We have performed a clinical trial to test this hypothesis in patients with advanced, refractory CRC with positive results. We have adapted our AI/digital pathology programme to develop a biomarker to select CRC patients who are more likely to benefit from this combination immunotherapy and plan to incorporate this into a prospective clinical trial.
Date: 1 March 2023, 12:00 (Wednesday, 7th week, Hilary 2023)
Venue: John Radcliffe Academic, Headington OX3 9DU
Venue Details: Conference Room, Academic Centre, Level 3, JR Hospital
Speaker: Prof David Kerr (Nuffield Division of Clinical Laboratory Sciences, Oxford)
Organising department: Nuffield Division of Clinical Laboratory Sciences
Organiser: Tina Garland (University of Oxford)
Organiser contact email address: tina.garland@ndcls.ox.ac.uk
Booking required?: Not required
Audience: Members of the University only
Editor: Tina Garland